ARWR Arrowhead Pharmaceuticals Inc
Price (delayed)
$19.9
Market cap
$2.51B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.16
Enterprise value
$2.98B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger
Highlights
The quick ratio has soared by 71% YoY but it has decreased by 10% from the previous quarter
The net income has dropped by 116% year-on-year and by 7% since the previous quarter
The company's revenue has shrunk by 99% YoY and by 30% QoQ
Key stats
What are the main financial stats of ARWR
Market
Valuations
Earnings
Shares outstanding
126.1M
Market cap
$2.51B
Enterprise value
$2.98B
Price to earnings (P/E)
N/A
Price to book (P/B)
47.09
Price to sales (P/S)
993.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,192.29
Revenue
$2.5M
Gross profit
$2.5M
Operating income
-$625.95M
Net income
-$639.71M
EBIT
-$590.43M
EBITDA
-$570.87M
Free cash flow
-$571.61M
Per share
Balance sheet
Liquidity
EPS
-$5.16
EPS diluted
-$5.16
Free cash flow per share
-$4.58
Book value per share
$0.42
Revenue per share
$0.02
TBVPS
$8.05
Total assets
$1.01B
Total liabilities
$957.62M
Debt
$525.27M
Equity
$52.59M
Working capital
$476.78M
Debt to equity
9.99
Current ratio
6.09
Quick ratio
5.92
Net debt/EBITDA
-0.83
Margins
Efficiency
Dividend
EBITDA margin
-22,834.7%
Gross margin
100%
Net margin
-25,588.6%
Operating margin
-25,037.9%
Return on assets
-64.1%
Return on equity
-243.2%
Return on invested capital
-52.3%
Return on capital employed
-64.2%
Return on sales
-23,617.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARWR stock price
How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-5.06%
1 week
-0.25%
1 month
0.71%
1 year
-31.8%
YTD
5.85%
QTD
5.85%
Financial performance
How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$2.5M
Gross profit
$2.5M
Operating income
-$625.95M
Net income
-$639.71M
Gross margin
100%
Net margin
-25,588.6%
The net income has dropped by 116% year-on-year and by 7% since the previous quarter
The operating income has dropped by 109% year-on-year and by 4.1% since the previous quarter
The company's revenue has shrunk by 99% YoY and by 30% QoQ
The gross profit has shrunk by 99% YoY and by 30% QoQ
Growth
What is Arrowhead Pharmaceuticals's growth rate over time
Valuation
What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
47.09
P/S
993.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,192.29
ARWR's EPS has plunged by 87% YoY and by 3.2% from the previous quarter
The price to book (P/B) is 153% higher than the last 4 quarters average of 18.6
The equity has plunged by 72% from the previous quarter and by 67% YoY
The price to sales (P/S) is 114% more than the last 4 quarters average of 464.0
The company's revenue has shrunk by 99% YoY and by 30% QoQ
Efficiency
How efficient is Arrowhead Pharmaceuticals business performance
The company's return on equity has shrunk by 155% YoY and by 18% QoQ
The company's return on assets has shrunk by 66% YoY but it rose by 3.6% QoQ
ARWR's ROS is down by 47% from the previous quarter
Arrowhead Pharmaceuticals's return on invested capital has decreased by 28% YoY but it has increased by 14% QoQ
Dividends
What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARWR.
Financial health
How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 6% higher than its total liabilities
The total liabilities has surged by 112% year-on-year
The quick ratio has soared by 71% YoY but it has decreased by 10% from the previous quarter
The equity has plunged by 72% from the previous quarter and by 67% YoY
Arrowhead Pharmaceuticals's debt has increased by 2.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.